The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the press and the medical community for its ability to trigger profound weight loss
This analysis showed that semaglutide (both oral and sc) reduces the continuum relative and the absolute risk of MACE, especially in medium to high-risk patients, with no difference between trials evaluating only blood glucose control or cardiovascular events, and also with studies without active comparator, only versus placebo
Nature 503 , 267271 (2013)
At my peak, I was taking 1.5 mg a week, and by the end of August, I officially hit my goal weight
FAQs: Wegovy vs
Other autoimmune conditions : People with conditions like thyroid disease, type 1 diabetes, rheumatoid arthritis, or alopecia areata have a higher risk